Report suggests Parkinson’s prevention linked to omega-3 fatty acid intake
DENVER A report released Wednesday links long-chain omega-3 polyunsaturated fatty acids with the prevention of Parkinson’s disease, according to the December 2007 Fats of Life and PUFA Newsletter electronic publications.
“Papers with the potential to redirect our thinking about diseases are rare, but this study from Laval University in Quebec City, Canada, might do it for Parkinson’s disease,” stated Fats of Life editor Joyce Nettleton. “The researchers showed that the consumption of marine omega-3s-mainly docosahexaenoic acid protected Parkinson’s animals from losing their dopamine-producing neurons. Animals without these omega-3s lost 30 percent of these essential cells, a hallmark of the disease. The implication is that sufficient brain DHA might be able to prevent the onset of Parkinson’s disease.”
Reckitt Benckiser makes $2.3 billion offer for Adams
CHESTER, N.J. Reckitt Benckiser Group on Friday commenced its previously announced cash tender offer for all of the outstanding shares of Adams Respiratory Therapeutics in a deal that would be worth $2.3 billion, first announced Dec. 10.
The deal will expire if not approved by Adams’ shareholders by Jan. 23.
The offer is being made through Twickenham, a wholly-owned subsidiary of Reckitt Benckiser. Adams’ board has unanimously determined that the offer is fair to and in the best interests of Adams’ stockholders and recommended that holders of Adams common stock accept the offer and tender their shares in the offer.
NAD finds in favor of Relaxane’s ad claims
NEW YORK The National Advertising Division of the Council of Better Business Bureaus has determined that advertising claims for Relaxane, a dietary supplement advertised by Indegene Pharmaceuticals to relieve the symptoms of stress, are supported by the evidence provided by the advertiser.
NAD examined labeling claims and Internet claims that included:
- “For the first time—a clinically tested non-addictive product that relieves the symptoms of everyday stress.”
- “Relaxane is effective in managing everyday stress, it alleviates multiple symptoms of everyday stress—frustration, irritability, restlessness, stress-related gastrointestinal discomforts (fullness, bloating, cramps) and stress-related minor muscle pain.”
- “Relaxane is designed to provide stress relief and address multiple symptoms of stress.”
- “Relaxane is an innovative stress reducer, clinically tested, optimized plant-derived Natural molecular composition of valeriana officinalis, melissa officinalis, passiflora incarnata and petasites hybridus that work on the multiple symptoms of stress.”
The advertiser presented as evidence three studies performed on the product.
Following its review of the evidence, NAD was satisfied that the challenged advertising clearly conveys that Relaxane is for, and has been tested for, relief and alleviation of the symptoms associated with stress. NAD determined as well that the advertiser provided a reasonable basis for a claim that Relaxane, when taken as directed, is non-addictive.
Indigene Pharmaceuticals, in its advertiser’s statement, said the company is pleased that NAD has found that claims for Relaxane are substantiated. “In particular,” the company stated, “Indigene Pharmaceuticals, is pleased that NAD has found that clinical testing on a Relaxane product itself is the gold standard for supporting advertising claims.”
NAD, the advertising industry’s self-regulatory forum, has expanded its review of dietary-supplement advertising, pursuant to a series of grants made by the Council for Responsible Nutrition.